美股新聞 標題聯播 · 近 24 小時 349 則 · 30 個來源 · 最新 9/20 04:16
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · NRIX近 30 天 1 則 · 第 1 / 1 頁
- Can KT-621 Mark a Turning Point for Kymera Therapeutics?
- Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
- Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
- Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins
- Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
- Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
- Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
- RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
- Company News for July 13, 2026
- Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
- Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
- Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
- Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade
- Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
- Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。